SRT2104

DRUG10 trials

Sponsors

GlaxoSmithKline, Sirtris, a GSK Company

Conditions

Atrophy, MuscularColitis, UlcerativeDiabetes Mellitus, Type 2Healthy VolunteerPsoriasisSepsis

Phase 1

A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers

CompletedNCT00933530

Sirtris, a GSK CompanyDiabetes Mellitus, Type 2, Healthy Volunteer

Start: 2008-05-31End: 2008-11-30Updated: 2017-05-30

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers

CompletedNCT00933062

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2009-03-23End: 2009-05-12Updated: 2017-07-07

A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days

CompletedNCT00964340

GlaxoSmithKlineAtrophy, Muscular

Start: 2009-10-01End: 2010-04-27Updated: 2017-06-16

Effect of SRT2104 on Endotoxin-induced Inflammation

CompletedNCT01014117

GlaxoSmithKlineSepsis

Start: 2009-12-09End: 2010-05-10Updated: 2017-06-22

A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

CompletedNCT01031108

Sirtris, a GSK CompanyDiabetes Mellitus, Type 2

Start: 2010-05-28End: 2011-10-12Updated: 2017-06-20

A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers

WithdrawnNCT01039909

GlaxoSmithKlineAtrophy, Muscular, Healthy Volunteer

Start: 2011-01-31End: 2011-02-28Updated: 2015-04-17

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

CompletedNCT01453491

Sirtris, a GSK CompanyColitis, Ulcerative

Start: 2012-02-13End: 2013-03-18Updated: 2017-06-01

Phase 2

Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

CompletedNCT00937326

Sirtris, a GSK CompanyDiabetes Mellitus, Type 2

Start: 2009-08-19End: 2010-09-18Updated: 2018-07-13

A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus

CompletedNCT01018017

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2010-03-03End: 2010-12-25Updated: 2017-04-25

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

CompletedNCT01154101

Sirtris, a GSK CompanyPsoriasis

Start: 2010-06-07End: 2011-11-09Updated: 2017-10-13

Related Papers

Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus

Open Heart2017-09-0126 citations

Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus

Open Heart2016-05-0133 citations

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

PLoS ONE2015-11-10100 citations

Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers.

2013-06-1474 citations

A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers.

2012-12-2097 citations